ArticleArthritis research & therapy2025

Comparative effectiveness of subcutaneous sarilumab 200 mg biweekly, subcutaneous Tocilizumab 162 mg biweekly, and intravenous Tocilizumab 8 mg/kg every 4 weeks in patients with rheumatoid arthritis: a prospective cohort study.

Akira Onishi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.